Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05184738
Other study ID # PEPTIDIC-AN-2021
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 15, 2021
Est. completion date September 2022

Study information

Verified date October 2021
Source Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Anorexia nervosa causes gastroparesis, constipation, and can lead to elevated liver enzymes. It is often necessary to supplement the diet of patients with nutritional formulas. The ingestion of a peptide formula, with partially hydrolyzed protein and rich in medium chain triglycerides, could favor its digestion and absorption, improving its tolerance and acceptance by the patient, compared to a polymeric formula.


Description:

Main objective: • To compare the digestive tolerance of an oligomeric nutritional supplement with respect to a polymeric nutritional supplement in a group of patients diagnosed with anorexia nervosa under follow-up by the Nutrition Unit. Secondary Objectives: - Assess the gastrointestinal tolerance of the oral nutritional supplement on a single occasion with respect to a continuous intake over a period of 4 weeks. - Evaluate the impact of oral nutritional supplementation on nutritional status over a four-week period. - Evaluate the impact of oral nutritional supplementation on the functional capacity of the patient in a period of four weeks. - Evaluate the impact of oral nutritional supplementation on the patient's body composition over a four-week period. - Evaluate the impact of oral nutritional supplementation on the quality of life of the patient in a period of four weeks. - Evaluate the impact of oral nutritional supplementation on the depressive and anxious symptoms of the patient in a period of four weeks.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 42
Est. completion date September 2022
Est. primary completion date March 15, 2022
Accepts healthy volunteers No
Gender All
Age group 12 Years to 40 Years
Eligibility Inclusion Criteria: - Male or female participants, = 12 y = 40 years of age at screening - Diagnosed of Anorexy nervous according to DSM-5 - Appropiate cultural level & understanding of the clinical study - To be in agreement in participate voluntarily in the study and written informed consent must be obtained from the participants. - Females who are non-pregnant and non-lactating women or women who have given birth at least six weeks before to the screening visit. Exclusion Criteria: - Allergy or intolerance to any component of the products under study. - Participation in a concomitant trial that conflicts with this study - Doesn't sign the informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Experimental Treatment, Oligomeric nutritional formula
Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
Control Treatment
Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).

Locations

Country Name City State
Spain Hospital Regional Universitario de Málaga Málaga Malaga

Sponsors (1)

Lead Sponsor Collaborator
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare the digestive tolerance of an oligomeric nutritional supplement with respect to a polymeric nutritional supplement in a group of patients diagnosed with anorexia nervosa under follow-up by the Nutrition Unit. Differences in the score of the questionnaire: "Evaluation questionnaire for gastrointestinal complaints". This questionnaire assesses the presence (and where appropriate its degree) or absence of nausea, vomiting, diarrhea, constipation, reflux or heartburn. Each section has a score from 0 to 10, which will be filled in by the patient himself. From baseline to week 1
Secondary Assess the gastrointestinal tolerance of the oral nutritional supplement on a single occasion with respect to a continuous intake over a period of 4 weeks. Difference in score in the questionnaire "Evaluation questionnaire for gastrointestinal complaints". This questionnaire assesses the presence (and where appropriate its degree) or absence of nausea, vomiting, diarrhea, constipation, reflux or heartburn. Each section has a score from 0 to 10, which will be filled in by the patient himself. From baseline to week 1 in group 1; from baseline to week 8 in group 2
Secondary Compare the sensory perception of a polymeric nutritional supplement with respect to an oligomeric one. Change in the score of the "Product sensory evaluation questionnaire". It consists of 11 items, which assess how the patient perceives the organoleptic characteristics of the product and their satisfaction after taking it. Each item consists of a score from 0 to 10 that the patient has to fill in. The items can refer to positive or negative characteristics of the product, so the level of score in each of them can indicate better or worse characteristics of the product depending on the characteristic in question. From baseline to week 1 in group 1; from baseline to week 8 in group 2
Secondary Compare adherence to treatment in group 2 subjects. Adherence will be determined by daily registration of the percentage they take of the supplement. From baseline to week 8 in group 2
Secondary Evaluate the intake of natural food in group 2 patients. Dietary registration of natural food intake at breakfast, mid-morning snack and lunch, in group 2 patients. It will be done through the DIETSTAT program. The total amount of calories and the percentage of macronutrients will be determined. From baseline to week 8 in group 2
Secondary Changes in weight Weight will be measured in kg From baseline to week 8
Secondary Change in hand grip strength It will be determined with a JAMAR dynamometer. The mean and maximum of three measurements made on the dominant hand and the mean and maximum of three measurements made on the non-dominant hand will be taken. The outside will be measured in kg. From baselilne to week 8
Secondary Change in fat mass Determined by AKERN bioimpedance analyzer and measured in kg From baselilne to week 8
Secondary Change in lean mass Determined by AKERN bioimpedance meter and measured in kg From baselilne to week 8
Secondary Change in extracellular water Determined by AKERN bioimpedance analyzer and measured in l From baselilne to week 8
Secondary Change in intracellular water Determined by AKERN bioimpedance analyzer and measured in l From baselilne to week 8
Secondary Change in phase angle Determined by AKERN bioimpedance analyzer and measured in degrees of angle From baselilne to week 8
Secondary Change in total cell mass Determined by AKERN bioimpedance analyzer and measured in kg From baselilne to week 8
Secondary Evaluate the impact of oral nutritional supplementation on the quality of life of the patient Changes in the score of the "SF-12 Health Questionnaire" questionnaire. This questionnaire is the adaptation made for Spain of the SF-12 Health Survey. The SF-12 is a shortened version of the SF-36 Health Questionnaire designed for uses where it is too long. Provides a health status profile. It consists of 12 items from the 8 dimensions of the SF-36 Physical Function (2), Social Function (1), Physical role (2), Emotional role (2), Mental health (2), Vitality (1), Body pain (1), General Health (1). The response options form Likert-type scales that assess intensity or frequency. The number of answer options ranges from three to six, depending on the item. For each of the 8 dimensions, the items are coded, added and transformed on a scale that ranges from 0 (the worst health status for that dimension) to 100 (the best health status). From baselilne to week 8
Secondary Changes in eating habits and styles Changes in the score of the "Eating Disorder Examination-Q (EDE-Q)" test. This questionnaire takes about 10 minutes to complete. It studies the scope and severity of the characteristics associated with the diagnosis of eating disorder. It includes 4 subscales: Restriction-diet, Preoccupation with food, Preoccupation with weight and Concern about the figure. Includes a definition of the term "binge" (eg, "episodes in which you have eaten an abnormally large amount of food under the circumstances" and experiencing a "loss of control" over eating). The EDE-Q generates two types of data: frequency data on key behavioral features of eating disorders in terms of number of episodes of the behavior, and subscale scores reflecting the severity of characteristics of eating disorders. Higher scores on the global scale and subscales denote more problematic eating behaviors and attitudes. From baselilne to week 8
Secondary Assess the impact of oral nutritional supplementation on the patient's depressive and anxious symptoms. Changes in the score of the "Hospital Anxiety and Depression Scale (HADS)". This aims to detect depressive and anxiety disorders in non-psychiatric hospital services, avoiding overlap with symptoms due to physical illness, without taking into account the physical aspects that may accompany anxiety / depression, only affecting the emotional ones. It is a self-administered scale with 14 items divided into 2 subscales (anxiety and depression) whose maximum score is 21 points for each of them. Based on the score obtained, patients can be classified as normal (<7), doubtful (between 8 and 10) and potential clinical case (= 11). The score is referred to the last week. From baseline to week 8
See also
  Status Clinical Trial Phase
Recruiting NCT05531604 - Appetitive Conditioning in Anorexia Nervosa
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Active, not recruiting NCT04883554 - Impact of an Olfactory Sensory Therapeutic Group for Adolescent Patients With Restrictive Anorexia Nervosa , Pilot Study N/A
Recruiting NCT04213820 - TMS and Body Image Treatment for Anorexia Nervosa N/A
Completed NCT03414112 - The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa Early Phase 1
Recruiting NCT06144905 - Norwegian Microbiota Study in Anorexia Nervosa
Not yet recruiting NCT05632497 - Alteration of Symbiosis Intestinal Microbiota on Patients With Anorexia Nervosa
Not yet recruiting NCT05682417 - Impact of Body Schema Distortion on Remission and Weight Regain in Anorexia Nervosa N/A
Not yet recruiting NCT04804800 - Virtual Reality Place in the Management of Body Dysmorphia Disorders in Anorexia Nervosa N/A
Not yet recruiting NCT03600610 - Evaluation of CARdiac Abnormalities by Echocardiography and MRI in Malnourished Patients Suffering From Anorexia Nervosa N/A
Completed NCT02745067 - Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa N/A
Completed NCT02382055 - Changing Habits in Anorexia Nervosa: Novel Treatment Development N/A
Completed NCT03075371 - Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa N/A
Terminated NCT02240797 - Kappa Opioid Receptor Imaging in Anorexia N/A
Completed NCT03144986 - Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa N/A
Unknown status NCT01761942 - Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Phase 2
Completed NCT01579682 - Adaptive Family Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT02551445 - A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders. N/A
Completed NCT00946816 - The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity N/A
Recruiting NCT00942929 - Lung Function Tests in Adolescents With Anorexia Nervosa N/A